NYSE: WAT

WATERS CORP /DE/

CIK 0001000697 · SIC 3826 · Lab Analytical Instruments

Large Revenue $3.2B Assets $24.8B as of Aug 16, 2026

Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.

Sign up free

Want to see a complete report first? Today's free report (HPQ 10-Q) is open in full — no account needed.

8-K Filed Aug 21, 2026 · Period ending Aug 17, 2026

Summary not yet generated.

10-Q Filed Aug 11, 2026 · Period ending Jul 4, 2026

revenue $1.65B, net income -$136.0M. Waters swings to operating loss as BDS acquisition closes; 113.4% workforce cut underway

5 material changes detected. Sign up free to read the summary.

Partner

Trade WAT commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

8-K Filed Aug 4, 2026 · Period ending Aug 4, 2026

Summary not yet generated.

8-K Filed May 22, 2026 · Period ending May 21, 2026

Waters Corp holds routine annual meeting; all directors re-elected, auditor ratified

2 material changes detected. Sign up free to read the summary.

10-Q Filed May 12, 2026 · Period ending Apr 4, 2026

revenue $1.27B, net income -$72.0M. Waters completes BD Biosciences acquisition, swings to Q1 loss on integration costs

5 material changes detected. Sign up free to read the summary.

8-K Filed May 5, 2026 · Period ending May 5, 2026

Waters Corporation reports Q1 2026 earnings for quarter ended April 4, 2026

2 material changes detected. Sign up free to read the summary.

8-K Filed Mar 23, 2026 · Period ending Mar 23, 2026

Waters completes $3.5B bond offering to refinance term loan taken out one month earlier

4 material changes detected. Sign up free to read the summary.

8-K Filed Mar 16, 2026 · Period ending Mar 16, 2026

Waters completes acquisition of BD's Biosciences unit, files S-3 for potential securities offering

3 material changes detected. Sign up free to read the summary.

10-K Filed Feb 23, 2026 · Period ending Dec 31, 2025

Summary not yet generated.

10-Q Filed Nov 4, 2025 · Period ending Sep 27, 2025

Summary not yet generated.

10-Q Filed Aug 4, 2025 · Period ending Jun 28, 2025

Summary not yet generated.

10-K Filed Feb 25, 2025 · Period ending Dec 31, 2024

Summary not yet generated.

Latest financial statements

From 10-Q filed Aug 11, 2026 (period ending Jul 4, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.

As filed

Consolidated Statements of Operations (Unaudited)

(In millions , except per share data)

Description Three months ended July 4, 2026 Three months ended June 28, 2025
Revenues:
Product revenue 1,220 473
Service revenue 425 298
Total net revenues 1,645 771
Costs and operating expenses:
Cost of product revenue 700 200
Cost of service revenue 211 121
Selling and administrative expenses 405 198
Research and development expenses 122 49
Purchased intangibles amortization 244 12
Restructuring charges 49 3
Total costs and operating expenses 1,731 583
Operating (loss) income (86) 188
Other expense, net (1)
Interest expense (60) (15)
Interest income 5 5
(Loss) income before income taxes (141) 178
Benefit (provision) for income taxes 5 (31)
Net (loss) income (136) 147
Net (loss) income per basic common share (1.39) 2.47
Weighted-average number of basic common shares 98,204 59,515
Net (loss) income per diluted common share (1.39) 2.47
Weighted-average number of diluted common shares and equivalents 98,204 59,656

Consolidated Balance Sheets (Unaudited)

(In millions, except share data)

Description July 4, 2026 December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents 539 588
Accounts receivable, net 1,987 829
Inventories 1,377 572
Other current assets 562 159
Total current assets 4,465 2,148
Property, plant and equipment, net 1,489 642
Intangible assets, net 8,521 558
Goodwill 9,421 1,340
Operating lease assets 366 81
Other assets 489 308
Total assets 24,751 5,077
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Notes payable 200 460
Accounts payable 863 104
Accrued employee compensation 214 100
Deferred revenue and customer advances 495 267
Current operating lease liabilities 51 31
Accrued income taxes 10 36
Accrued warranty 21 12
Other current liabilities 545 230
Total current liabilities 2,399 1,239
Long-term liabilities:
Long-term debt 4,886 947
Long-term deferred tax liabilities 1,705 37
Long-term operating lease liabilities 317 53
Long-term portion of retirement benefits 59 44
Long-term income tax liabilities 32 34
Other long-term liabilities 158 161
Total long-term liabilities 7,157 1,276
Total liabilities 9,556 2,515
Commitments and contingencies (Notes 6, 7 and 10)
Stockholders’ equity:
Preferred stock, par value $0.01 per share, 5,000 shares authorized, none issued at July 4, 2026 and December 31, 2025
Common stock, par value $0.01 per share, 400,000 shares authorized, 201,881 and 163,162 shares issued, 98,225 and 59,549 shares outstanding at July 4, 2026 and December 31, 2025, respectively 2 2
Additional paid-in capital 15,312 2,416
Retained earnings 10,223 10,431
Treasury stock, at cost, 103,656 and 103,613 shares at July 4, 2026 and December 31, 2025, respectively (10,176) (10,162)
Accumulated other comprehensive loss (166) (125)
Total stockholders’ equity 15,195 2,562
Total liabilities and stockholders’ equity 24,751 5,077

Consolidated Statements of Cash Flows (Unaudited)

(In millions)

Description Six months ended July 4, 2026 Six months ended June 28, 2025
Cash flows from operating activities:
Net (loss) income (208) 268
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation 45 26
Deferred income taxes 114 2
Depreciation 71 44
Amortization of intangibles 437 57
Amortization of acquisition-related inventory and fixed assets step-up recognized 253
Change in operating assets and liabilities:
(Increase) decrease in accounts receivable (782) 43
Increase in inventories (68) (36)
Increase in other current assets (354) (12)
Decrease in other assets 17 14
Increase (decrease) in accounts payable and other current liabilities 557 (164)
Increase in deferred revenue and customer advances 116 64
Decrease in other liabilities (5)
Net cash provided by operating activities 198 301
Cash flows from investing activities:
Additions to property, plant, equipment and software capitalization (87) (49)
Cash acquired in business acquisition 144 (35)
Investments in unaffiliated companies, net (10) (1)
Change in deposit asset, related to deferred close entities 51
Net cash provided by (used in) investing activities 97 (85)
Cash flows from financing activities:
Proceeds from debt issuances 3,742 70
Payments on debt (4,040) (240)
Payments of debt issuance costs (28) (5)
Proceeds from stock plans 15 13
Purchases of treasury shares (14) (14)
(Payments for) proceeds from derivative contracts (12) 2
Net cash used in financing activities (337) (174)
Effect of exchange rate changes on cash and cash equivalents (7)
(Decrease) increase in cash and cash equivalents (49) 42
Cash and cash equivalents at beginning of period 588 325
Cash and cash equivalents at end of period 539 367
Non-cash investing activities related to the BDS Business Acquisition:
Fair value of Waters common stock issued 12,835
Notes payable and debt assumed 4,000
Estimated net working capital adjustment 121

Amounts as printed on the EDGAR/iXBRL face — (In millions , except per share data); (In millions, except share data); (In millions). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗

View AI report for this filing